Menarini, Italy’s top drugmaker (€3.5bn), targets acquisition in Asia

The Italian daily La Repubblica today published a long article about the Menarini pharmaceutical group. The company is reportedly seeking an acquisition in Asia, and the target is said to be a non-specified company’s product portfolio. The group has a workforce of 16,000, with 250 new employees each year, and revenues of €3.5bn (EBITDA €440m), only 27% of which from the Italian market. Menarini is Italy’s top pharmaceutical company, before Chiesi (€1.6bn in revenues), Bracco (€1.3bn), Recordati (€1.2bn) and Zambon (€700m).
(Source: La Repubblica)